Fusion Pharmaceuticals Inc.

8.16+0.0100+0.12%Vol 36.08K1Y Perf -52.35%
Jun 14th, 2021 16:00 DELAYED
BID8.16 ASK8.25
Open8.08 Previous Close8.15
Pre-Market- After-Market-
 - -  - -%
Target Price
22.25 
Analyst Rating
— — 0.00
Potential %
172.67 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap346.45M 
Earnings Rating
Price Range Ratio 52W %
12.51 
Earnings Date
24th Jun 2021

Today's Price Range

8.088.36

52W Range

6.6119.00

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-4.56%
1 Month
-0.24%
3 Months
-31.31%
6 Months
-37.66%
1 Year
-52.35%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FUSN8.160.01000.12
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.29-0.42-44.83
Q04 2020-0.19-0.32-68.42
Q03 2020-0.22-0.24-9.09
Q02 2020-0.42-2.99-611.90
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date24th Jun 2021
Estimated EPS Next Report-0.29
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume36.08K
Shares Outstanding42.46M
Trades Count542
Dollar Volume579.66K
Avg. Volume44.09K
Avg. Weekly Volume35.01K
Avg. Monthly Volume36.08K
Avg. Quarterly Volume39.82K

Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) stock closed at 8.16 per share at the end of the most recent trading day (a 0.12% change compared to the prior day closing price) with a volume of 80.54K shares and market capitalization of 346.45M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 61 people. Fusion Pharmaceuticals Inc. CEO is John Valliant.

The one-year performance of Fusion Pharmaceuticals Inc. stock is -52.35%, while year-to-date (YTD) performance is -30.55%. FUSN stock has a five-year performance of %. Its 52-week range is between 6.61 and 19, which gives FUSN stock a 52-week price range ratio of 12.51%

Fusion Pharmaceuticals Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 1.24, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -46.20%, a ROC of -48.60% and a ROE of -50.76%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Fusion Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.29 for the next earnings report. Fusion Pharmaceuticals Inc.’s next earnings report date is 24th Jun 2021.

The consensus rating of Wall Street analysts for Fusion Pharmaceuticals Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Fusion Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Fusion Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Fusion Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 48.86, ATR14 : 0.46, CCI20 : -3.26, Chaikin Money Flow : 0.12, MACD : -0.14, Money Flow Index : 42.50, ROC : -0.49, RSI : 43.58, STOCH (14,3) : 31.11, STOCH RSI : 0.31, UO : 47.67, Williams %R : -68.89), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Fusion Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.

CEO: John Valliant

Telephone: +1 905 730-6046

Address: 270 Longwood Road South, Hamilton L8P 0A6, ON, CA

Number of employees: 61

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

News

Stocktwits